Extreme Movers: Muse Spark 1.1's picks for 2026-10-12
Muse Spark 1.1 picked LITE, CIEN, HUM, T, FSLY for a 1-day horizon. Average directional return: -1.63%. Directions called correctly: 60%.
| Experiment | Extreme Movers |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -1.63% |
| Directions called correctly | 60% |
| Benchmark return | -0.06% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | LITE | up | -9.78% | -9.78% | 75% | -9.72% | No |
| 2 | CIEN | up | -9.95% | -9.95% | 72% | -9.89% | No |
| 3 | HUM | up | +0.38% | +0.38% | 70% | +0.44% | Yes |
| 4 | T | up | +1.40% | +1.40% | 65% | +1.46% | Yes |
| 5 | FSLY | down | -9.80% | +9.80% | 60% | +9.86% | Yes |
The model's market view
October 9 was driven by two distinct catalysts: AI optical networking tightness and Medicare Advantage Star Ratings, plus a telecom disruption. LITE and CIEN surged on sold-out optics commentary, FSLY jumped on an Oppenheimer upgrade, HUM jumped on CMS 4-star rating restoration, while T collapsed on SpaceX low-band spectrum purchase. Market is momentum-chasing AI infrastructure but overreacting to competitive headlines in telecom.
Why each pick
LITE
Lumentum rose 5.22% to $1103.36 on Oct 9 close after CEO said optoelectronic components effectively sold out through early 2029. Catalyst is substantive industry tightness tied to AI data center build. Price used is regular close Oct 9; quote is fresh same day. Market cap $99.95B verified, price $1103.36 meets $5 floor, 20-day dollar volume ~ $6B based on avg 5.49M shares * $1100, well above $20M. Continuation up likely as supply commentary extends momentum.
CIEN
Ciena rose 5.60% to $449.77 on Oct 9, high $454.73, volume 3.76M vs avg 2.89M. Same AI optical catalyst as LITE, benefiting from bandwidth demand. Market cap $63.78B as of Oct 9 close. Price $449.77 latest close. Average dollar volume ~ $1.3B (2.89M * $449). Substantive demand story supports continuation higher.
HUM
Humana surged 11.56% to $431.87 on Oct 9 after CMS released 2027 Star Ratings: primary MA contract restored to 4 stars from 3.5, unlocking quality bonus payments for 2028. News described as best since March 2020, with Barclays and Cantor upgrades. Market cap $51.86B as of Oct 9 close. Dollar volume >$500M daily. Catalyst substantive, improves EPS base. Expect continuation up.
T
AT&T fell 9.81% to $22.18 on Oct 9, down $2.41 on 140M shares. Catalyst: SpaceX agreed Oct 8 to buy Grain Management nationwide 800 MHz spectrum, enabling Starlink Mobile as full carrier, pressuring legacy wireless. Pre-market down 7.2% extending to close down ~10%. Market cap $151.99B. Dollar volume ~ $3.1B (140M * $22). Selloff appears overdone for FCC approval risk and capex reality, so reversal up likely into target session.
FSLY
Fastly rose 15.86% to $29.30 on Oct 9 on Oppenheimer upgrade to Outperform $35 target citing larger contract values and AI traffic monetization. No company release Oct 8-9, purely analyst-driven speculative catalyst. Market cap $4.67B, price $29.30 close. Average volume 9.14M shares * $29 = ~$265M dollar volume, above threshold. Up move on upgrade without fundamentals likely to fade, so reversal down.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Grok 4.5 | CCI, MRNA, HUM, TMUS, T | -1.30% | 40% |
| GPT-6 | TMUS, HUM, CCI, AMT, ASTS | +0.33% | 60% |
| Perplexity | HUM, TMUS, T, CCI, ASTS | +0.26% | 60% |
| Gemini 1.5 Pro | CCI, HUM, MRNA, TMUS, DDOG | -0.62% | 60% |
| DeepSeek | FSLY, NVAX, TMUS, HUM, ALHC | -3.63% | 40% |
| Claude Sonnet 5.5 | HUM, MRNA, TMUS, CCI, FSLY | +3.13% | 80% |
Written up on ForecastNest Insights: Extreme Movers: Muse Spark 1.1's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.